Xenon Pharmaceuticals (NASDAQ:XENE) Stock Picked Up by Analysts at Guggenheim

Posted by Brenda Bartman on Oct 8th, 2026

Research analysts at Guggenheim initiated coverage on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. The firm set a “buy” rating and a $73.00 price target on the biopharmaceutical company’s stock. Guggenheim’s target price points to a potential upside of 100.49% from the stock’s previous close.

XENE has been the topic of a number of other reports. Robert W. Baird lowered their price target on shares of Xenon Pharmaceuticals from $97.00 to $90.00 and set an “outperform” rating on the stock in a research note on Friday, September 18th. Wall Street Zen upgraded shares of Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 3rd. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $46.00 price objective (down from $90.00) on shares of Xenon Pharmaceuticals in a report on Friday, September 18th. Jefferies Financial Group restated a “buy” rating and set a $90.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday, September 28th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Xenon Pharmaceuticals in a report on Friday, September 18th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Xenon Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $70.14.

Get Our Latest Stock Analysis on XENE

Xenon Pharmaceuticals Price Performance

Shares of XENE stock opened at $36.41 on Tuesday. The business’s fifty day moving average price is $54.65 and its 200 day moving average price is $56.65. Xenon Pharmaceuticals has a 1-year low of $35.75 and a 1-year high of $72.66. The firm has a market capitalization of $3.52 billion, a PE ratio of -7.68 and a beta of 0.60.

Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.05. During the same period in the previous year, the firm posted ($1.07) earnings per share. Equities research analysts expect that Xenon Pharmaceuticals will post -4.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, CEO Ian Mortimer acquired 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 30th. The shares were acquired at an average cost of $37.38 per share, for a total transaction of $1,121,400.00. Following the transaction, the chief executive officer directly owned 49,923 shares of the company’s stock, valued at approximately $1,866,121.74. This represents a 150.58% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Thomas Patrick Kelly acquired 15,000 shares of the stock in a transaction that occurred on Wednesday, September 30th. The stock was acquired at an average cost of $37.32 per share, for a total transaction of $559,800.00. Following the completion of the purchase, the chief financial officer owned 15,000 shares in the company, valued at $559,800. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 2.91% of the company’s stock.

Institutional Trading of Xenon Pharmaceuticals

Large investors have recently modified their holdings of the business. BlackRock Inc. acquired a new position in shares of Xenon Pharmaceuticals in the second quarter worth $454,057,000. Jupiter Topco LLC acquired a new stake in shares of Xenon Pharmaceuticals during the second quarter valued at $252,673,000. Orbimed Advisors LLC boosted its stake in shares of Xenon Pharmaceuticals by 137.0% during the first quarter. Orbimed Advisors LLC now owns 1,059,971 shares of the biopharmaceutical company’s stock valued at $61,637,000 after acquiring an additional 612,771 shares during the last quarter. Siren L.L.C. increased its position in Xenon Pharmaceuticals by 62.2% during the 1st quarter. Siren L.L.C. now owns 1,318,564 shares of the biopharmaceutical company’s stock worth $76,674,000 after purchasing an additional 505,803 shares in the last quarter. Finally, Octagon Capital Advisors LP purchased a new stake in Xenon Pharmaceuticals during the 1st quarter worth about $28,494,000. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Company Profile

(Get Free Report)

Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders. The company uses research in ion channels and neuronal signaling to identify potential treatments for conditions with significant unmet medical needs.

Xenon’s lead investigational medicine is azetukalner, also known as XEN1101, a selective potassium channel opener being evaluated for epilepsy and major depressive disorder. The company is also advancing additional programs aimed at genetically defined epilepsies and other disorders of the central nervous system.